Written by Markus Horneber, Elke Wolf and the CAM-Cancer Consortium.
Updated February 28, 2017

Propagermanium

Is it safe ?

A review from 1997 reported on 31 cases of organ toxicity related to different germanium compounds, including GeO2, germanium-lactate-citrate and propagermanium (Ge-132), which were ingested over a period from two to 36 months. In the two cases of propagermanium intake contamination with GeO2 was detected 9. All cases showed renal impairment in terms of chronic or acute renal failure, which caused death in nine cases. Other clinical findings were anaemia, which occurred in all cases, gastrointestinal disturbances, weight loss, myopathy and liver dysfunction9. If at all, renal function improved very slowly and remained impaired in some patients observed as long as 40 months 23-24. As a consequence, governmental institutions of several countries imposed alerts because of possible injury to health.

According to data from animal studies, inorganic germanium compounds cause renal toxicity, whereas propagermanium does not 25. However, French investigators found evidence that at least in rats, higher doses of propagermanium could also cause structural changes in the kidneys 26.

Adverse effects

In a case series with 10 myeloma patients, depression was seen as an adverse effect attributed to propagermanium in two patients 16. In a double-blind placebo-controlled trial on the treatment of chronic hepatitis B with daily doses of 30 mg propagermanium including 182 patients no adverse events attributable to propagermanium were reported. A post-market survey including 32,700 patients with chronic hepatitis B reported liver enzyme flares in 4% of patients treated with propagermanium. As a consequence, severely impaired liver function is regarded a contraindication for the application of propagermanium in Japan 20.

Quality problems

Germanium dioxide (GeO2) represents an intermediate product in the synthesis of organic germanium compounds9. Thus contamination of organic germanium compounds is possible if manufacturers do not safeguard the purity of their products.

Citation

Markus Horneber, Elke Wolf, CAM-Cancer Consortium. Propagermanium [online document]. http://cam-cancer.org/The-Summaries/Dietary-approaches/Propagermanium. February 28, 2017.

Document history

Assessed as up to date in April 2016 by Barbara Wider.
Assessed as up to date in April 2016 by Barbara Wider.
Assessed as up to date in March 2015 by Barbara Wider.
Assessed as up to date in January 2013 by Markus Horneber.
Summary first published in April 2011, authored by Markus Horneber.

References

  1. A new Element: Germanium. Lancet 127, 562 (1886).
  2. Asai, K. Organisches Germanium - Eine Hoffnung für viele Kranke. Semmelweis-Verlag, 27316 Hoya (2001).
  3. Schroeder, H. A. & Balassa, J. J. Abnormal trace metals in man: germanium. J Chronic Dis 20, 211-224 (1967).
  4. Hara, S. et al. Determination of germanium in some plants and animals. Z Naturforsch [C] 45, 1250-1251 (1990).
  5. Lewis, B. L., Frolich, P. N. & Andreae, M. O. Methylgermanium in natural waters. Nature 313, 303-305 (1985).
  6. Expert group on vitamins and minerals. Risk assessment - Germanium. http://www.food.gov.uk/multimedia/pdfs/evm_germanium.pdf (last access: 02.06.2010). 2003.
  7. Mironov, V. F., Berliner, E. M. & Gar, T. K. Reactions of Trichlorogermane with Acrylic Acid and its Derivatives. Zhurnal Obshchei Khimil 37 Nr. 4, 962. 1967.
  8. Kaplan, B. J., Parish, W. W., Andrus, G. M., Simpson, J. S. & Field, C. J. Germane facts about germanium sesquioxide: I. Chemistry and anticancer properties. J Altern Complement Med 10, 337-344 (2004).
  9. Tao, S. H. & Bolger, P. M. Hazard assessment of germanium supplements. Regul Toxicol Pharmacol 25, 211-219 (1997).
  10. Kaplan, B. J., Andrus, G. M. & Parish, W. W. Germane facts about germanium sesquioxide: II. Scientific error and misrepresentation. J Altern Complement Med 10, 345-348 (2004).
  11. Suzuki, F., Brutkiewicz, R. R. & Pollard, R. B. Importance of T-cells and macrophages in the antitumor activity of carboxyethylgermanium sesquioxide (Ge-132). Anticancer Res 5, 479-483 (1985).
  12. Suzuki, F., Brutkiewicz, R. R. & Pollard, R. B. Ability of sera from mice treated with Ge-132, an organic germanium compound, to inhibit experimental murine ascites tumours. Br J Cancer 52, 757-763 (1985).
  13. Suzuki, F., Brutkiewicz, R. R. & Pollard, R. B. Cooperation of Lymphokine(s) and Macrophages in Expression of Antitumor Activity of Carboxyethylgermanium Sesquioxide (Ge-132). Anticancer Res 6, 177-182 (1986).
  14. Aso, H. et al. Induction of interferon and activation of NK cells and macrophages in mice by oral administration of Ge-132, an organic germanium compound. Microbiol Immunol 29, 65-74 (1985).
  15. Miyao, K., Onishi, T., Asai, K., Tomizawa, S. & Suzuki, F. Current Chemotherapy and Infectious diseases. Nelson, J. D. (ed.), pp. 1527-1529 (American society of Microbiology, Washington DC,1980).
  16. Tsutsumi, Y. et al. Effectiveness of propagermanium treatment in multiple myeloma patients. Eur J Haematol 73, 397-401 (2004).
  17. Mizushima, Y., Satoh, H. & Miyao, K. Germanium in biologischen Systemen. Lekim, D. & Samochowiec, L. (eds.), pp. 189-210 (Semmelweis-Verlag, 27316 Hoya,2007).
  18. FDA-import alert no.54-07. FDA-import alert no.54-07. 10-2-2009. Ref Type: Electronic Citation
  19. Bundesinstitut für gesundheitlichen Verbraucherschutz und Veterinärmedizin Warnung vor Germanium. Dtsch Ärztebl 97, 2418 (2000).
  20. Hirayama, C., Suzuki, H., Ito, M., Okumura, M. & Oda, T. Propagermanium: a nonspecific immune modulator for chronic hepatitis B. J Gastroenterol 38, 525-532 (2003).
  21. Brutkiewicz, R. R. & Suzuki, F. Biological activities and antitumor mechanism of an immunopotentiating organogermanium compound, Ge-132 (review). In Vivo 1, 189-203 (1987).
  22. Mainwaring, M. G., Poor, C., Zander, D. S. & Harman, E. Complete remission of pulmonary spindle cell carcinoma after treatment with oral germanium sesquioxide. Chest 117, 591-593 (2000).
  23. Hess, B. et al. Tubulointerstitial nephropathy persisting 20 months after discontinuation of chronic intake of germanium lactate citrate. Am J Kidney Dis 21, 548-552 (1993).
  24. Sanai, T. et al. Germanium dioxide-induced nephropathy: a new type of renal disease. Nephron 54, 53-60 (1990).
  25. Sanai, T. et al. Chronic tubulointerstitial changes induced by germanium dioxide in comparison with carboxyethylgermanium sesquioxide. Kidney Int 40, 882-890 (1991).
  26. Anger, F., Anger, J. P., Guillou, L., Sado, P. A. & Papillon, A. [Subacute and subchronic oral toxicity of beta-bis carboxyethyl sesquioxide of germanium in the rat]. J Toxicol Clin Exp 11, 421-436 (1991).